[A20-80] Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

Last updated 01.12.2020

Project no.:

Commission awarded on 28.08.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Muscles, bones and joints


Adults with active psoriatic arthritis who responded inadequately to DMARD therapy

Result of dossier assessment:

For under 65 year olds with concomitant moderate to severe plaque psoriasis who responded inadequately to DMARD therapy (except bDMARDs), under secukinumab alone: hint of considerable added benefit; other constellations: added benefit not proven


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2021-02-18: A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form